scholarly journals Human Papillomavirus (Cervical Cancer) Vaccine Update

2017 ◽  
Vol 13 (2) ◽  
pp. 176-177
Author(s):  
Denise M. Linton
Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 230 ◽  
Author(s):  
Ian H. Frazer

Cervical cancer is initiated by infection of cervical epithelium with human papillomavirus. Vaccines have been developed, incorporating papillomavirus viral capsids and alum based adjuvants. In extensive clinical trials these vaccines have been shown safe and effective in preventing infection with, and disease caused by, the papillomavirus genotypes they incorporate, in women not already infected. These vaccines have the potential to reduce the global burden of cervical cancer by up to 70%.


2019 ◽  
Vol 4 (2) ◽  
pp. 252-262
Author(s):  
Yani Suryani ◽  
Opik Taupiqurrohman ◽  
Muhammad Yusuf ◽  
Toto Subroto ◽  
Sukma Nuswantara

 The aims of this study were to carry out testing of the early 4 protein of type 16 HPV through immunoinformatics meth-ods in an effort to get the peptide vaccine candidate for cervical cancer. The software used are IEDB-AR, CABSdock and Accelrys Discovery Study 4.5. Based on the analysis that sequence of ami-no acid lysine, leucine, leucine, glycine, serine, threonine, tryp-tophan, proline and threonine (KLLGSTWPT) and the sequence of amino acid tyrosine, tyrosine, valine, leucine, histidine, leucine, cysteine, leucine, alanine, alanine, threonine, lysine, tyrosine, pro-line and leucine (YYVLHLCLAATKYPL) are peptide vaccine can-didate for cervical cancer from the early 4 protein of HPV type 16 


Vaccine ◽  
2013 ◽  
Vol 31 (52) ◽  
pp. 6266 ◽  
Author(s):  
Marc Arbyn ◽  
Guglielmo Ronco ◽  
Ahti Anttila ◽  
Chris J.L.M. Meijer ◽  
Mario Poljak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document